853950-77-3 Usage
Uses
Used in Pharmaceutical Industry:
Esomeprazole is used as a therapeutic agent for the treatment of acid-related disorders such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. Its application is based on its ability to inhibit the proton pump, which leads to a significant reduction in gastric acid production. This reduction helps alleviate symptoms and promotes healing of the affected tissues.
Used in Gastroenterology:
In the field of gastroenterology, Esomeprazole is utilized as a medication to manage conditions that involve excessive stomach acid production. By inhibiting the proton pump, it effectively reduces acid secretion, providing relief from heartburn, regurgitation, and other symptoms associated with GERD and peptic ulcers.
Used in Drug Formulation:
Esomeprazole is used in the formulation of delayed-release capsules or tablets, which are designed to release the active ingredient in the small intestine, thus minimizing the risk of degradation by stomach acid and ensuring optimal absorption. This formulation approach enhances the bioavailability and therapeutic efficacy of the drug.
Check Digit Verification of cas no
The CAS Registry Mumber 853950-77-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,3,9,5 and 0 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 853950-77:
(8*8)+(7*5)+(6*3)+(5*9)+(4*5)+(3*0)+(2*7)+(1*7)=203
203 % 10 = 3
So 853950-77-3 is a valid CAS Registry Number.
853950-77-3Relevant academic research and scientific papers
Raju, Manne Naga,Kumar, Neelam Uday,Reddy, Baddam Sudhakar,Anitha, Naredla,Srinivas, Gangula,Bhattacharya, Apurba,Mukkanti, Kagga,Kolla, Naveenkumar,Bandichhor, Rakeshwar
, p. 5464 - 5466 (2011)
An alternative and scalable synthesis of dexlansoprazole ((R)-(+)-1); the (R)-enantiomer of Lansoprazole with an enantiomeric excess of >99.8% is presented.
DEXLANSOPRAZOLE PROCESS AND POLYMORPHS
-
Page/Page column 55, (2009/10/22)
Processes for the preparation of dexlansoprazole, an amorphous form of dexlansoprazole, a solid dispersion of amorphous dexlansoprazole and a pharmaceutically acceptable carrier, and processes for their preparation. Also provided are crystalline compounds 2-[(R)-[(4-chloro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and 2-[(R)-[(4-nitro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, and methods for their preparation.
